Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients

Samankaltaisia teoksia

• Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial
  Tekijä: Cooper, David A., et al.
  Julkaistu: (2016)
• Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
  Tekijä: Takeshi Nishijima, et al.
  Julkaistu: (2013-01-01)
• Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
  Tekijä: Nishijima, Takeshi, et al.
  Julkaistu: (2013)
• Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
  Tekijä: Smith, Kimberly Y, et al.
  Julkaistu: (2008)
• Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
  Tekijä: Jackson, Akil, et al.
  Julkaistu: (2010)